The FDA utility for patritumab deruxtecan in handled EGFR-mutant lung most cancers was withdrawn after confirmatory trial knowledge missed survival objectives.
The biologics license utility (BLA) looking for accelerated approval for patritumab deruxtecan (HER3-DXd) for grownup sufferers with beforehand handled, domestically superior/metastatic EGFR-mutated non-small cell lung most cancers (NSCLC) within the U.S. has been voluntarily withdrawn.
This determination is predicated on knowledge from the confirmatory part 3 HERTHENA-Lung02 trial, in accordance with a information launch from Merck, which introduced the withdrawal.
“EGFR-mutated non-small cell lung most cancers has confirmed to be difficult-to-treat within the second-line metastatic setting and past,” mentioned Dr. Ken Takeshita, World Head of R&D at Daiichi Sankyo, said within the information launch. “Whereas we’re upset with the general survival outcomes of HERTHENA-Lung02, we’re conducting additional biomarker analyses to higher determine sufferers that will profit from patritumab deruxtecan to information our continued growth in lung most cancers. We stay assured within the broad growth program of this HER3 directed antibody drug conjugate, which at present consists of a number of medical trials throughout 15 sorts of most cancers.”
“Lung most cancers is likely one of the main causes of cancer-related deaths worldwide and these outcomes are a reminder of how difficult it may be to deal with sufferers with EGFR-mutated non-small cell lung most cancers within the second and later line settings,” continued Dr. Eliav Barr, senior vp, head of World Scientific Growth, and chief medical officer at Merck Analysis Laboratories. “We wish to thank the sufferers, their households and investigators for his or her participation on this research.”
Diving into the Information that Result in the Withdrawal
Topline total survival knowledge from HERTHENA-Lung02 fueled the choice to withdraw the patritumab deruxtecan BLA on this affected person inhabitants, as the general survival outcomes didn’t meet statistical significance. Discussions with the U.S. Meals and Drug Administration (FDA) supported the regulatory withdrawal, as properly. Notably, the whole response letter that Merck obtained from the FDA in June of 2024 just isn’t associated to this withdrawal, because the letter detailed findings pertaining to an inspection of a third-party manufacturing facility, in accordance with the information launch.
Extra data on the part 3 trial which led to the withdrawal can be shared throughout an oral presentation on the 2025 American Society of Scientific Oncology (ASCO) Annual Assembly on Sunday, June 1, 2025, the place investigators will even share beforehand reported statistically important progression-free survival along with topline total survival outcomes.
“The protection profile seen in HERTHENA-Lung02 was in line with that noticed for patritumab deruxtecan in earlier lung most cancers medical trials with no new security alerts recognized,” the information launch mentioned on security with patritumab deruxtecan.
The worldwide, multicenter, open-label HERTHENA-Lung02 trial is investigating the efficacy and security of patritumab deruxtecan monotherapy (5.6 milligrams per kilogram [mg/kg]) each three weeks) monotherapy in contrast with the 4 cycles of doublet chemotherapy consisting of platinum plus pemetrexed induction adopted by pemetrexed upkeep. That is being evaluated in sufferers with superior NSCLC harboring EGFR mutations (exon 19 deletion or L858R) whose illness has progressed following therapy with a third-generation EGFR tyrosine kinase inhibitor (TKI).
Per the research protocol, sufferers who expertise a tumor response will proceed therapy with both patritumab deruxtecan or chemotherapy till illness development, as decided by the investigator. Contrarily, for sufferers on receiving the chemotherapy routine with out illness development after 4 cycles are allowed to proceed upkeep pemetrexed therapy with no restriction on the variety of cycles
The first finish level of the trial is progression-free survival as evaluated by blinded unbiased central overview (BICR). Secondary finish factors embody total survival, goal response price, length of response, medical profit price, time to response, illness management price and security. Mind imaging was carried out for enrolled sufferers to allow analysis of intracranial finish factors, together with intracranial progression-free survival as decided by BICR.
Throughout Asia, Europe, North America and Oceania, HERTHENA-Lung02 enrolled 586 sufferers.
Extra Info on EGFR-Mutated NSCLC and Patritumab Deruxtecan
In 2022, roughly 2.5 million lung most cancers instances had been identified globally. Lung most cancers stays essentially the most regularly identified most cancers and the main explanation for cancer-related mortality worldwide. Non–small cell lung most cancers (NSCLC) represents roughly 87% of all lung most cancers instances, and in the US and Europe, roughly as much as 15% of sufferers with NSCLC have an EGFR mutation.
For sufferers whose tumors harbor EGFR mutations, the usual first-line therapy within the metastatic setting consists of EGFR-targeted remedy, with or with out platinum-based chemotherapy, bettering affected person outcomes. Nonetheless, illness development happens usually, necessitating further traces of remedy.
To deal with this unmet want, investigators are evaluating patritumab deruxtecan. The agent is an investigational antibody-drug conjugate concentrating on HER3 and consists of a totally human anti-HER3 IgG1 monoclonal antibody connected to a topoisomerase I inhibitor payload by way of cleavable tetrapeptide-based linkers.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
